Pyxis Oncology to acquire Apexigen for $16m.

Pyxis Oncology, a clinical-stage company focused on developing next-generation therapeutics, agreed to acquire Apexigen, a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, for $16m. “This acquisition uniquely positions Pyxis Oncology at the forefront of antibody-drug conjugate innovation by adding humanized antibody generation to our Flexible Antibody Conjugation Technology ADC toolkit acquired from Pfizer, and expands our clinical pipeline into Phase 2 in select solid tumor types by leveraging our founding heritage of immuno-oncology expertise—all while maintaining our cash runway into 2025," Lara S. Sullivan, Pyxis Oncology M.D., President and CEO.